Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.

@article{Chinnapongse2012ImmunogenicityAL,
  title={Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.},
  author={Robert B Chinnapongse and Mark F. Lew and Joaquim J. Ferreira and Kristen L Gullo and Paul R Nemeth and Yuxin Zhang},
  journal={Clinical neuropharmacology},
  year={2012},
  volume={35 5},
  pages={215-23}
}
OBJECTIVE Therapeutic botulinum toxins are antigenic proteins with the potential to produce antibodies (Abs). It is, however, unclear whether Abs to Myobloc® (rimabotulinumtoxinB, botulinum toxin type B, BoNT-B) impact the efficacy and safety of BoNT-B treatment of cervical dystonia (CD). The objective was to determine if Abs to BoNT-B impact the efficacy… CONTINUE READING